Abstract
First-line ADP-A2M4CD8 T-cell Receptor T-cell Therapy plus Pembrolizumab in Head and Neck Cancers: An Additional Cohort of the Phase 1 SURPASS Trial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have